Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.

Dixon JM, Cameron DA, Arthur LM, Axelrod DM, Renshaw L, Thomas JS, Turnbull A, Young O, Loman CA, Jakubowski D, Baehner FL, Singh B.

Adv Ther. 2019 Apr;36(4):828-841. doi: 10.1007/s12325-019-0896-0. Epub 2019 Mar 11.

PMID:
30859501
2.

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.

Selli C, Turnbull AK, Pearce DA, Li A, Fernando A, Wills J, Renshaw L, Thomas JS, Dixon JM, Sims AH.

Breast Cancer Res. 2019 Jan 7;21(1):2. doi: 10.1186/s13058-018-1089-5.

3.

Intra-operative assessment of excised breast tumour margins using ClearEdge imaging device.

Dixon JM, Renshaw L, Young O, Kulkarni D, Saleem T, Sarfaty M, Sreenivasan R, Kusnick C, Thomas J, Williams LJ.

Eur J Surg Oncol. 2016 Dec;42(12):1834-1840. doi: 10.1016/j.ejso.2016.07.141. Epub 2016 Aug 10.

PMID:
27591938
4.

Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.

Pearce DA, Arthur LM, Turnbull AK, Renshaw L, Sabine VS, Thomas JS, Bartlett JM, Dixon JM, Sims AH.

Sci Rep. 2016 Jul 7;6:29434. doi: 10.1038/srep29434.

5.

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.

Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, Kay C, Harrison DJ, Kunkler IH, Langdon SP.

Oncotarget. 2015 Sep 22;6(28):24856-70. doi: 10.18632/oncotarget.4498.

6.

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH, Dixon JM.

J Clin Oncol. 2015 Jul 10;33(20):2270-8. doi: 10.1200/JCO.2014.57.8963. Epub 2015 Jun 1.

7.

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M.

Breast Cancer Res. 2015 Mar 11;17:35. doi: 10.1186/s13058-015-0532-0.

8.

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM.

Breast Cancer Res Treat. 2014 Aug;147(1):211-9. doi: 10.1007/s10549-014-3080-x. Epub 2014 Aug 9.

PMID:
25104442
9.

Molecular changes in lobular breast cancers in response to endocrine therapy.

Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, Kay C, Thomas JS, Dixon JM, Sims AH.

Cancer Res. 2014 Oct 1;74(19):5371-6. doi: 10.1158/0008-5472.CAN-14-0620. Epub 2014 Aug 6.

10.

Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.

Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, Sims AH.

BMC Med Genomics. 2012 Aug 21;5:35. doi: 10.1186/1755-8794-5-35.

11.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308
12.

FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG.

J Clin Invest. 2012 Jul;122(7):2543-53. doi: 10.1172/JCI61405. Epub 2012 Jun 25.

13.

Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.

Dixon JM, Renshaw L, Dixon J, Thomas J.

Breast Cancer Res Treat. 2011 Dec;130(3):871-7. doi: 10.1007/s10549-011-1735-4. Epub 2011 Aug 26.

PMID:
21870129
14.

Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization.

Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N, Richards WG.

Calcif Tissue Int. 2011 Aug;89(2):140-50. doi: 10.1007/s00223-011-9501-5. Epub 2011 Jun 3.

15.

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.

Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM.

Breast Cancer Res Treat. 2011 Aug;128(3):725-34. doi: 10.1007/s10549-010-0967-z. Epub 2010 Oct 13.

PMID:
20941539
16.

Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.

Dixon JM, Renshaw L, Langridge C, Young OE, McHugh M, Williams L, Murray J, Macaskill EJ, McCaig F, Dixon OM, Fallowfield LJ.

Breast Cancer Res Treat. 2011 Feb;125(3):741-9. doi: 10.1007/s10549-010-1091-9. Epub 2010 Sep 7.

PMID:
20821047
17.

Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.

Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JM.

Breast Cancer Res Treat. 2010 Jul;122(2):419-28. doi: 10.1007/s10549-010-0928-6. Epub 2010 May 18.

PMID:
20480226
18.

Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles.

Kitchen RR, Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, van Hemert JI, Dixon JM, Bartlett JM.

BMC Genomics. 2010 Feb 24;11:134. doi: 10.1186/1471-2164-11-134.

19.

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.

Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM.

Clin Cancer Res. 2010 Mar 1;16(5):1605-12. doi: 10.1158/1078-0432.CCR-09-1623. Epub 2010 Feb 23.

20.

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.

Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C.

Breast Cancer Res Treat. 2010 Apr;120(2):461-7. doi: 10.1007/s10549-010-0747-9. Epub 2010 Jan 28.

PMID:
20107891
21.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.

McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.

Breast Cancer Res Treat. 2010 Feb;119(3):643-51. doi: 10.1007/s10549-009-0646-0.

PMID:
19941160
22.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.

23.

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.

J Clin Oncol. 2009 Mar 20;27(9):1382-7. doi: 10.1200/JCO.2008.16.8849. Epub 2009 Feb 17.

PMID:
19224856
24.

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.

Murray J, Young OE, Renshaw L, White S, Williams L, Evans DB, Thomas JS, Dowsett M, Dixon JM.

Breast Cancer Res Treat. 2009 Apr;114(3):495-501. doi: 10.1007/s10549-008-0027-0. Epub 2008 Apr 26.

PMID:
18438705
25.

Src inhibitors in early breast cancer: a methodology, feasibility and variability study.

Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvin P, Womack C, Clack G, Dixon JM.

Breast Cancer Res Treat. 2009 Mar;114(2):211-21. doi: 10.1007/s10549-008-9997-1. Epub 2008 Apr 14.

PMID:
18409068
26.

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.

Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M.

J Clin Oncol. 2008 Apr 1;26(10):1671-6. doi: 10.1200/JCO.2007.13.9279.

PMID:
18375896
27.

Increase in response rate by prolonged treatment with neoadjuvant letrozole.

Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR.

Breast Cancer Res Treat. 2009 Jan;113(1):145-51. doi: 10.1007/s10549-008-9915-6. Epub 2008 Feb 9.

PMID:
18264759
28.

Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.

Young OE, Renshaw L, Macaskill EJ, White S, Faratian D, Thomas JS, Dixon JM.

Eur J Cancer. 2008 Feb;44(3):391-9. Epub 2007 Dec 20.

PMID:
18083023
29.

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.

Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM.

Pharmacogenet Genomics. 2007 Oct;17(10):813-26.

PMID:
17885619
30.

Aromatase inhibitors--gene discovery.

Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM.

J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):130-42. Epub 2007 May 29.

PMID:
17616392
31.

DCIS and aromatase inhibitors.

Dixon JM, Faratian D, White S, Renshaw L, Murray J, Young O, Macaskill EJ, Williams L, Thomas J, Evans DB.

J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):173-9. Epub 2007 May 24.

PMID:
17604618
32.
33.

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM.

J Clin Oncol. 2006 Jul 1;24(19):3019-25. Epub 2006 Jun 5.

PMID:
16754938
34.

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.

Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ.

Br J Cancer. 2006 Apr 10;94(7):1051-6.

35.

Surgical issues surrounding use of aromatase inhibitors.

Dixon JM, Renshaw L, Murray J, Macaskill EJ, Young O, Miller WR.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):97-103.

PMID:
16023854
36.

Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.

Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA, Anderson TJ, Miller WR, Dowsett M.

Eur J Cancer. 2004 Dec;40(18):2742-7.

PMID:
15571956
37.

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.

Dixon JM, Jackson J, Renshaw L, Miller WR.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):295-9. Review.

PMID:
14623524
38.
39.

Lessons from the use of aromatase inhibitors in the neoadjuvant setting.

Dixon JM, Love CD, Renshaw L, Bellamy C, Cameron DA, Miller WR, Leonard RC.

Endocr Relat Cancer. 1999 Jun;6(2):227-30. Review.

PMID:
10731113
40.

How important is the scientific literature in guiding clinical decisions? The case of magnetic resonance imaging.

Ramsey SD, Hillman AL, Renshaw LR, Kimberly JR, Pauly MV, Schwartz JS.

Int J Technol Assess Health Care. 1993 Spring;9(2):253-62.

PMID:
8458704
41.

Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP.

McMillan R, Tani P, Millard F, Berchtold P, Renshaw L, Woods VL Jr.

Blood. 1987 Oct;70(4):1040-5.

PMID:
3651598
42.

Transplantation of T-lymphocyte-depleted bone marrow between HLA-mismatched individuals.

Spruce WE, McMillan R, Miller W, Fox R, Carson D, Schwartz DB, Hartman GA, Renshaw LW, Beutler E.

Transplantation. 1983 Oct;36(4):369-72.

PMID:
6353702
43.

Circa-annual rhythms of prolactin secretion in ewes and the effect of pinealectomy.

Munro CJ, McNatty KP, Renshaw L.

J Endocrinol. 1980 Jan;84(1):83-9. No abstract available.

PMID:
7359082
44.

Influence of Cortisone on the C'4 Titer in Guinea Pigs.

Guthrie RK, Renshaw L, Elliott AY.

Can J Comp Med Vet Sci. 1960 Apr;24(4):122-5. No abstract available.

Supplemental Content

Loading ...
Support Center